Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients who can walk be allowed to take its gene therapy Elevidys again.

Net revenue1 of 1,346 million euros, up 2.9%, sustained by organic growth of +2.3% Acceleration in organic growth during the second quarter of ...

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...

Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...

Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug ...

Wall Street traders left stocks at all-time highs while the dollar climbed the most since May, with a tariff deal between ...

Arrowhead said it has met both of these conditions in a July 28 release and now expects to receive the $100 million within 60 days. The company also said it plans on reaching the second enrollment ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from ...

Wall Street kicked off a pivotal week with the dollar climbing the most since May as a tariff deal between President Donald ...

Arrowhead Pharmaceuticals Inc. said Monday that it’s owed a $100 million milestone payment from Sarepta Therapeutics Inc. within the next two months, pressuring the beleaguered biotech company just ...

The “Facioscapulohumeral Muscular Dystrophy - Pipeline Insight, 2025” report covers drug profiles, clinical stages, and therapeutic assessments. Key players include Avidity Biosciences and Hoffmann-La ...